Skip to main content

Table 1 Baseline characteristics of 340 HIV positive adults by antiretroviral treatment initiated1

From: Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir

  Tenofovir based regimen (n = 279) Non tenofovir-based regimen (n = 60) P
Age, years <  0.001
 18–25 50 (17.9) 22 (36.7)  
 26–35 134 (48.0) 31 (51.7)  
 36–45 66 (23.7) 6 (10.0)  
  > 45 29 (10.4) 1 (1.7)  
Sex 0.003
 Males 101 (36.2) 10 (16.7)  
 Females 178 (63.8) 50 (83.3)  
WHO Stage 0.78
 I 84 (30.1) 15 (25.0)  
 II 82 (29.4) 19 (31.7)  
 III 89 (31.9) 22 (36.7)  
 IV 24 (8.6) 4 (6.7)  
 Weight, kg 49.2 (44.1; 54.3) 47.3 (42.1; 51.3) 0.08
 Fat Free mass, Kg 39.0 (35.2; 44.8) 37.1 (33.7; 40.1) 0.01
 Fat mass, kg 8.4 (6.0; 11.9) 9.9 (7.2; 11.6) 0.49
 Height, m 1.60 (1.54; 1.67) 1.6 (1.5; 1.6) 0.02
 Body mass index, kg/m2 18.9 (17.4; 20.6) 18.3 (17.2; 20.5) 0.78
 On tuberculosis treatment, Yes 30 (10.8) 5 (8.3) 0.58
 C-reactive protein, mg/L 2.0 (0.6, 7.7) 1.9 (0.4; 6.8) 0.57
 CD4 count, cells/ul 178 (111; 243) 192 (122; 231) 0.45
 Serum phosphate, mmol/La 1.3 (0.3)) 1.3 (0.3)) 0.89
 Hepatitis B surface antigen positive2, Yes 10 (3.7) 2 (3.6) 0.97
 Viral load, log (copies+ 1/mL) 4.8 (4.3; 5.4) 4.8 (4.3; 5.2) 0.79
 Urine Protein dipstick positive3, Yes 14 (2.3) 1 (6.6) 0.28
 eGFR, ml/min/1.73m2 a 117.7 (21.7) 122 (18.0) 0.13
  1. eGFR Estimated glomerular filtration rate.
  2. 1 Data shown as median (IQR) or n (%) and a mean (±SD)
  3. 2n = 330 3n = 255